The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study

Delgado-Ortega, L.; González-Domínguez, Almudena; Borrás, Josep María; Oliva‐Moreno, Juan; González-Haba, Eva; Menjón, Salomón; Pérez, Pedro; Vicente, David; Cordero, Luis; Jiménez, M. Casado; Simón, Susana; Hidalgo, Álvaro; Moya-Alarcón, Carlota

doi:10.1007/s10198-018-0986-y

Cited by 17 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gordon et al reported that in women with primary epithelial ovarian cancer, treatment costs increased with later stage at diagnosis and more than one lines of chemotherapy [17]. Similar results were reported by Delgado-Ortega et al using Markov models to simulate cohorts of women with epithelial ovarian cancer in Spain [18]. Using health economic models, Rocconi et al showed that the incremental cost-effectiveness ratio was not favorable after the second line of chemotherapy in patients with platinum resistant epithelial ovarian cancer [19].…”

supporting

confidence: 53%

Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

et al. 2020

View full text Add to dashboard Cite

Aim: To describe the direct healthcare costs associated with repeated cytotoxic chemotherapy treatments for recurrent high-grade serous cancer (HGSC) of the ovaries. Patients & methods: Retrospective review of 66 women with recurrent stage III/IV HGSC ovarian cancer treated with repeated lines of cytotoxic chemotherapy in a Canadian University Tertiary Center. Results: Mean cost of treatment of first relapse was CAD$52,227 increasing by 38% for two, and 86% for three or more relapses with median overall survival of 36.0, 50.7 and 42.8 months, respectively. In-hospital care accounted for 71% and chemotherapy drugs accounted for 17% of the total costs. Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs.

show abstract

supporting

confidence: 53%

Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Genetic testing to HGEOC patients allows registering patients with hereditary cancer that may transmit gBRCA1/2m to their descendants, and, therefore, may be useful for designing effective public health programmes against cancer to the target population. As was shown in the Ovarcost study, investing in techniques for early diagnosis may imply higher survival rates and a substantial reduction in the economic burden of cancer, due to possible cost savings at advanced disease stages [26]. It is worth noting that if all gBRCA1/2m carriers accepted to undergo RRS, the number of BC and EOC patients would be decreased and that the ICUR of the germline BRCA1/2 testing would be lower than our base-case result (€31,621.33/QALY).…”

Section: Discussionmentioning

confidence: 95%

“…It should also be noted that the simulation did not consider other benefits that germline BRCA1/2 testing may have on patients, such as providing information on the most appropriate therapy choice [9]. Besides, healthy gBRCA1/2m carriers who choose not to undergo RRS would still receive surveillance visits and tests that may imply higher benefits like earlier diagnosis of cancer, which may turn out in higher overall and disease-free survival rates [9,26].…”

Section: Discussionmentioning

confidence: 99%

“…The cost of EOC management was previously estimated in the Ovarcost study. The average annual cost per patient was €17,067 and €15,042 with and without surgical therapy, respectively [26]. As the survival rate for BC is higher than the one registered among EOC patients, the simulation applied the cost of BC management in the first year after the diagnosis [11].…”

Section: Costsmentioning

confidence: 99%

See 1 more Smart Citation

Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain

et al. 2019

Self Cite

View full text Add to dashboard Cite

Purpose Germline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC). The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer (HGEOC) patients without family history of OC or BC and the subsequent testing and management of their relatives with gBRCA1/2m in Spain. Methods/patients Incident HGEOC patients without family history of OC or BC who were gBRCA1/2m carriers and their relatives were simulated in a 50-year time horizon. The study compared two scenarios: BRCA1/2 testing vs no testing, using the perspective of the Spanish National Health Service. Cancer risk among gBRCA1/2m carriers was estimated based on their age and whether they had undergone risk-reducing surgeries. Direct healthcare costs and utilities of patients who developed EOC and BC were also included. A probabilistic sensitivity analysis (PSA) with 5 thousand simulations was developed considering ± 25% of the base-case value. Results The BRCA1/2-testing scenario amounted to €13,437,897.43 while the no-testing scenario amounted to €12,053,291.17. It was estimated that the screening test improved the quality of life among the patients' relatives by 43.8 quality-adjusted life years (QALYs). The incremental cost-utility ratio (ICUR) was €31,621.33/QALY in the base case. The PSA showed that 89.12% of the simulations were below the €50,000/QALY threshold. Conclusion Providing this screening test to HGEOC patients and their relatives is cost-effective and it allows one to identify a target population with high risk of cancer to provide effective prevention strategies.

show abstract

“…Other studies have attempted to estimate the costs of cancer on a population level but these were either for the short term [9,55,56] and/or focused on selected type/s of cancer [8,[57][58][59][60][61][62][63][64]. For example, Luengo-Fernandez et al [55] performed a population-based cost analysis for breast, colorectal, lung and prostate cancer across the European Union (27 countries) from a societal perspective, including healthcare costs, informal care costs and productivity losses.…”

Section: Discussionmentioning

confidence: 99%

Lifetime Costs of Surviving Cancer—A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study

Merollini

Gordon

Aitken

et al. 2020

IJERPH

View full text Add to dashboard Cite

Australia-wide, there are currently more than one million cancer survivors. There are over 32 million world-wide. A trend of increasing cancer incidence, medical innovations and extended survival places growing pressure on healthcare systems to manage the ongoing and late effects of cancer treatment. There are no published studies of the long-term health service use and cost of cancer survivorship on a population basis in Australia. All residents of the state of Queensland, Australia, diagnosed with a first primary malignancy from 1997–2015 formed the cohort of interest. State and national healthcare databases are linked with cancer registry records to capture all health service utilization and healthcare costs for 20 years (or death, if this occurs first), starting from the date of cancer diagnosis, including hospital admissions, emergency presentations, healthcare costing data, Medicare services and pharmaceuticals. Data analyses include regression and economic modeling. We capture the whole journey of health service contact and estimate long-term costs of all cancer patients diagnosed and treated in Queensland by linking routinely collected state and national healthcare data. Our results may improve the understanding of lifetime health effects faced by cancer survivors and estimate related healthcare costs. Research outcomes may inform policy and facilitate future planning for the allocation of healthcare resources according to the burden of disease.

show abstract

The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study

Cited by 17 publications

References 33 publications

Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain

Lifetime Costs of Surviving Cancer—A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study

Contact Info

Product

Resources

About